PROK PROKIDNEY CORP

ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that ProKidney’s CEO, Bruce Culleton, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event.

43rd Annual J.P. Morgan Healthcare Conference

Date:January 15, 2025
Time:7:30am PST
Format:Presentation
Webcast:
  

The live webcast will also be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at . Following the completion of the event, a replay will be available for 90 days.

About ProKidney Corp.

ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit .

Investor Contacts:

ProKidney

Ethan Holdaway

LifeSci Advisors, LLC

Daniel Ferry



EN
07/01/2025

Underlying

PROKPROKIDNEY CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PROKIDNEY CORP

 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Announces Alignment with the FDA on the Accelerated Approval...

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for both accelerated approval and for full approvalNearly half of the patients required for the accelerated approval analysis using eGFR slope have been enrolledTopline data to support an application for accelerated approval is anticipated in Q2 2027 WINSTON-SALEM, N.C., July 15, ...

20h / 51m 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virt...

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference: H.C. Wainwright 4th Annual Kidney Virtual ConferenceDate:Monday, July 14, 2025Time:1:30pm ETFormat:Fireside ChatWebcast: The live webc...

July 9, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Reports Statistically and Clinically Significant Topline Res...

ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney Week as a late-breaking clinical trialIn Group 1 (n=24), kidney function stabilized in patients randomized to receive two rilparencel injections (one in each kidney). The annual decline in eGFR slope improved by 78% from -5.8 mL/min/1.73m2 in the pre-injection period to -1.3 mL/min/1.73m2 in the pe...

July 8, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Corp. Completes Domestication from the Cayman Islands to Del...

ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware WINSTON-SALEM, N.C., July 01, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the completion of the domestication process to change the jurisdiction of incorporation of the Company from the Cayman Islands to Delaware. The domestication was approved by shareholders of the Company at its Annual General Meeting held on May 29, 2025. Effective as of July 1, 2025, ...

July 1, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Reports First Quarter 2025 Financial Results and Business Hi...

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additional details on the accelerated pathway are expected in mid-2025 after our planned Type B meeting with the FDAEnded the first quarter with $328.5 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Cor...

May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch